Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Sponsor: Rapport Therapeutics Inc.
Summary
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
312
Start Date
2026-06
Completion Date
2029-09
Last Updated
2026-07-22
Healthy Volunteers
No
Conditions
Interventions
RAP-219
RAP-219 medium dose tablets administered orally daily
RAP-219
RAP-219 low dose tablets administered orally daily
Placebo
Matching placebo tablets administered orally
Locations (5)
Pillar Clinical Research
Bentonville, Arkansas, United States
Colorado Springs Neurological Associates
Colorado Springs, Colorado, United States
K2 Medical Research
Maitland, Florida, United States
Velocity Clinical Research
Raleigh, North Carolina, United States
University of Texas Health Science Center in Houston
Houston, Texas, United States